ClinicalTrials.gg

Program

IM96

A development code. Also written as “IM96 CAR-T Cells” and “IM96 CAR-T cells”.

Its studies are mostly in Colorectal Neoplasms · Digestive System Neoplasms, led by Imunopharm Technology.

Furthest: phase 1, since Dec 2, 20243 company-led studies, 2 open or runningNext primary completion: May 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Imunopharm Technology32 open or runningphase 1since Dec 2, 2024Mar 10, 2022May 5, 2027phase 1 · NCT07406984

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 10, 2022First study: early phase 1 study in Digestive System NeoplasmsFirst studyNCT05287165 · 19 enrolled · China
  2. Dec 2, 2024Phase 1 study in Colorectal NeoplasmsNCT06718738 · 9 planned · China
  3. Feb 6, 2026Phase 1 study in Adenocarcinoma of GastricNCT07406984 · 18 planned · China

Ahead

  1. May 5, 2027Primary completion: phase 1 study in Adenocarcinoma of GastricNCT07406984

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07406984Adenocarcinoma of Gastric · China1Not yet recruitingMay 5, 202718
NCT06718738Colorectal Neoplasms · China1RecruitingAug 15, 20259
NCT05287165Digestive System Neoplasms · ChinaEarly 1UNKNOWNApr 30, 202419

How it is read

Names in the registry

  • “IM96 CAR-T Cells”, 2 entries
  • “IM96 CAR-T cells”, 1 entry

Codes read as this program: IM96.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.